Rank,Term name,P-value,Z-score,Combined score,Overlapping genes,Adjusted p-value,Old p-value,Old adjusted p-value,gene count
1,Ribosome,9.81218322906039e-07,8.33811475409836,115.35340551586256,"['RPL34', 'RPLP1', 'RPL36A', 'RPS3A', 'RPL10A', 'RPL9', 'RPL7', 'RPS15A', 'RPL36AL', 'RPS18', 'FAU', 'RPL26', 'RPS12']",9.910305061350993e-05,0,0,13
2,Coronavirus disease,0.0001595539041904612,4.3475409836065575,38.011110502652315,"['RPL34', 'RPLP1', 'RPL36A', 'RPS3A', 'RPL10A', 'RPL9', 'RPL7', 'RPS15A', 'RPL36AL', 'RPS18', 'FAU', 'RPL26', 'RPS12']",0.00805747216161829,0,0,13
3,Thermogenesis,0.012427803441611176,3.4257659073055775,15.031641091668046,"['NDUFAF8', 'UQCRB', 'NDUFS6', 'COX14', 'ATP5F1E', 'ATP5MF', 'CREB5']",0.4184027158675762,0,0,7
4,Biosynthesis of unsaturated fatty acids,0.02952771969138149,17.805555555555557,62.71874838397494,"['FADS2', 'ACOT7']",0.6837879061733649,0,0,2
5,Insulin secretion,0.07472747752670483,3.8329979879275653,9.942441906793492,"['KCNMB2', 'STX1A', 'CREB5']",0.6837879061733649,0,0,3
6,Huntington disease,0.07870565221669229,2.2720588235294117,5.775665107827232,"['UQCRB', 'NDUFS6', 'TBPL1', 'STX1A', 'ATP5F1E', 'CREB5']",0.6837879061733649,0,0,6
7,"Growth hormone synthesis, secretion and action",0.08578616811463886,5.916666666666667,14.530726852925925,"['CREB5', 'MAP2K6']",0.6837879061733649,0,0,2
8,Synthesis and degradation of ketone bodies,0.10335170144206614,inf,inf,['HMGCS1'],0.6837879061733649,0,0,1
9,Terpenoid backbone biosynthesis,0.10335170144206614,inf,inf,['HMGCS1'],0.6837879061733649,0,0,1
10,Basal transcription factors,0.10335170144206614,inf,inf,['TBPL1'],0.6837879061733649,0,0,1
11,Butanoate metabolism,0.10335170144206614,inf,inf,['HMGCS1'],0.6837879061733649,0,0,1
12,"Valine, leucine and isoleucine degradation",0.10335170144206614,inf,inf,['HMGCS1'],0.6837879061733649,0,0,1
13,alpha-Linolenic acid metabolism,0.10335170144206614,inf,inf,['FADS2'],0.6837879061733649,0,0,1
14,Fatty acid elongation,0.10335170144206614,inf,inf,['ACOT7'],0.6837879061733649,0,0,1
15,Amphetamine addiction,0.1202402962462261,4.430555555555555,9.385082211806742,"['STX1A', 'CREB5']",0.6837879061733649,0,0,2
16,NF-kappa B signaling pathway,0.1202402962462261,4.430555555555555,9.385082211806742,"['LTBR', 'CD14']",0.6837879061733649,0,0,2
17,Viral carcinogenesis,0.1683514894221224,2.4238156209987194,4.318515409537018,"['TBPL1', 'LTBR', 'CREB5']",0.6837879061733649,0,0,3
18,Human T-cell leukemia virus 1 infection,0.1683514894221224,2.4238156209987194,4.318515409537018,"['TBPL1', 'LTBR', 'CREB5']",0.6837879061733649,0,0,3
19,SNARE interactions in vesicular transport,0.1961515375437305,8.780821917808218,14.302797796229848,['STX1A'],0.6837879061733649,0,0,1
20,Vasopressin-regulated water reabsorption,0.1961515375437305,8.780821917808218,14.302797796229848,['CREB5'],0.6837879061733649,0,0,1
21,Cocaine addiction,0.1961515375437305,8.780821917808218,14.302797796229848,['CREB5'],0.6837879061733649,0,0,1
22,Cortisol synthesis and secretion,0.1961515375437305,8.780821917808218,14.302797796229848,['CREB5'],0.6837879061733649,0,0,1
23,Fc epsilon RI signaling pathway,0.1961515375437305,8.780821917808218,14.302797796229848,['MAP2K6'],0.6837879061733649,0,0,1
24,Mucin type O-glycan biosynthesis,0.1961515375437305,8.780821917808218,14.302797796229848,['GALNT10'],0.6837879061733649,0,0,1
25,Other types of O-glycan biosynthesis,0.1961515375437305,8.780821917808218,14.302797796229848,['GALNT10'],0.6837879061733649,0,0,1
26,RNA degradation,0.1961515375437305,8.780821917808218,14.302797796229848,['ENO4'],0.6837879061733649,0,0,1
27,TNF signaling pathway,0.19633514137651073,2.9444444444444446,4.7933558485893855,"['CREB5', 'MAP2K6']",0.6837879061733649,0,0,2
28,cGMP-PKG signaling pathway,0.19633514137651073,2.9444444444444446,4.7933558485893855,"['KCNMB2', 'CREB5']",0.6837879061733649,0,0,2
29,PPAR signaling pathway,0.19633514137651073,2.9444444444444446,4.7933558485893855,"['FADS2', 'HMGCS1']",0.6837879061733649,0,0,2
30,Oxidative phosphorylation,0.22942013073426992,1.7771428571428571,2.6163102905816933,"['UQCRB', 'NDUFS6', 'ATP5F1E', 'ATP5MF']",0.7480047641473914,0,0,4
31,Synaptic vesicle cycle,0.2767118409868315,2.201388888888889,2.8282973336504695,"['SLC6A1', 'STX1A']",0.7480047641473914,0,0,2
32,Toll-like receptor signaling pathway,0.2767118409868315,2.201388888888889,2.8282973336504695,"['CD14', 'MAP2K6']",0.7480047641473914,0,0,2
33,Amoebiasis,0.27946345666687883,4.383561643835616,5.588531464384869,['CD14'],0.7480047641473914,0,0,1
34,Ether lipid metabolism,0.27946345666687883,4.383561643835616,5.588531464384869,['PLA2G7'],0.7480047641473914,0,0,1
35,Glycolysis / Gluconeogenesis,0.27946345666687883,4.383561643835616,5.588531464384869,['ENO4'],0.7480047641473914,0,0,1
36,Relaxin signaling pathway,0.27946345666687883,4.383561643835616,5.588531464384869,['CREB5'],0.7480047641473914,0,0,1
37,Hepatitis B,0.31701970914575517,1.9537037037037037,2.2443978822136956,"['CREB5', 'MAP2K6']",0.7480047641473914,0,0,2
38,AMPK signaling pathway,0.3542455470585893,2.9178082191780823,3.0279991606276053,['CREB5'],0.7480047641473914,0,0,1
39,Thyroid hormone synthesis,0.3542455470585893,2.9178082191780823,3.0279991606276053,['CREB5'],0.7480047641473914,0,0,1
40,Vascular smooth muscle contraction,0.3542455470585893,2.9178082191780823,3.0279991606276053,['KCNMB2'],0.7480047641473914,0,0,1
41,Glycosaminoglycan biosynthesis,0.3542455470585893,2.9178082191780823,3.0279991606276053,['CHST15'],0.7480047641473914,0,0,1
42,GnRH signaling pathway,0.3542455470585893,2.9178082191780823,3.0279991606276053,['MAP2K6'],0.7480047641473914,0,0,1
43,"Parathyroid hormone synthesis, secretion and action",0.3542455470585893,2.9178082191780823,3.0279991606276053,['CREB5'],0.7480047641473914,0,0,1
44,Protein digestion and absorption,0.3542455470585893,2.9178082191780823,3.0279991606276053,['COL18A1'],0.7480047641473914,0,0,1
45,HIF-1 signaling pathway,0.35683016197128836,1.7555555555555555,1.8090918317094051,"['LTBR', 'ENO4']",0.7480047641473914,0,0,2
46,Aldosterone synthesis and secretion,0.42136037120485653,2.184931506849315,1.8883638115454076,['CREB5'],0.7480047641473914,0,0,1
47,Spliceosome,0.42136037120485653,2.184931506849315,1.8883638115454076,['SNRPD1'],0.7480047641473914,0,0,1
48,Cushing syndrome,0.42136037120485653,2.184931506849315,1.8883638115454076,['CREB5'],0.7480047641473914,0,0,1
49,Glucagon signaling pathway,0.42136037120485653,2.184931506849315,1.8883638115454076,['CREB5'],0.7480047641473914,0,0,1
50,Hematopoietic cell lineage,0.42136037120485653,2.184931506849315,1.8883638115454076,['CD14'],0.7480047641473914,0,0,1
51,Inflammatory mediator regulation of TRP channels,0.42136037120485653,2.184931506849315,1.8883638115454076,['MAP2K6'],0.7480047641473914,0,0,1
52,Intestinal immune network for IgA production,0.42136037120485653,2.184931506849315,1.8883638115454076,['LTBR'],0.7480047641473914,0,0,1
53,Osteoclast differentiation,0.42136037120485653,2.184931506849315,1.8883638115454076,['MAP2K6'],0.7480047641473914,0,0,1
54,PD-L1 expression and PD-1 checkpoint pathway in cancer,0.42136037120485653,2.184931506849315,1.8883638115454076,['MAP2K6'],0.7480047641473914,0,0,1
55,Diabetic cardiomyopathy,0.430840994806907,1.3140845070422535,1.1064804148568013,"['UQCRB', 'NDUFS6', 'ATP5F1E']",0.7480047641473914,0,0,3
56,Pathways of neurodegeneration,0.4423722740065264,1.1848805327066196,0.9663927125355245,"['UQCRB', 'NDUFS6', 'STX1A', 'ATP5F1E', 'MAP2K6']",0.7480047641473914,0,0,5
57,Human cytomegalovirus infection,0.4703690776093322,1.3440170940170941,1.0137082554849643,"['CREB5', 'MAP2K6']",0.7480047641473914,0,0,2
58,Human papillomavirus infection,0.4703690776093322,1.3440170940170941,1.0137082554849643,"['TBPL1', 'CREB5']",0.7480047641473914,0,0,2
59,Acute myeloid leukemia,0.48158435952813883,1.7452054794520548,1.2751760269178278,['CD14'],0.7480047641473914,0,0,1
60,Viral protein interaction with cytokine and cytokine receptor,0.48158435952813883,1.7452054794520548,1.2751760269178278,['LTBR'],0.7480047641473914,0,0,1
61,Longevity regulating pathway,0.48158435952813883,1.7452054794520548,1.2751760269178278,['CREB5'],0.7480047641473914,0,0,1
62,Mitophagy,0.48158435952813883,1.7452054794520548,1.2751760269178278,['TOMM7'],0.7480047641473914,0,0,1
63,Prion disease,0.4984739821251053,1.1262672811059908,0.7841116547049001,"['UQCRB', 'NDUFS6', 'ATP5F1E', 'CREB5']",0.7480047641473914,0,0,4
64,Alcoholism,0.5356163003157746,1.452054794520548,0.9065718709484184,['CREB5'],0.7480047641473914,0,0,1
65,Systemic lupus erythematosus,0.5356163003157746,1.452054794520548,0.9065718709484184,['SNRPD1'],0.7480047641473914,0,0,1
66,Cellular senescence,0.5356163003157746,1.452054794520548,0.9065718709484184,['MAP2K6'],0.7480047641473914,0,0,1
67,Estrogen signaling pathway,0.5356163003157746,1.452054794520548,0.9065718709484184,['CREB5'],0.7480047641473914,0,0,1
68,Insulin resistance,0.5356163003157746,1.452054794520548,0.9065718709484184,['CREB5'],0.7480047641473914,0,0,1
69,Prostate cancer,0.5356163003157746,1.452054794520548,0.9065718709484184,['CREB5'],0.7480047641473914,0,0,1
70,Amyotrophic lateral sclerosis,0.5447246524103425,1.0545454545454545,0.6406098280280645,"['UQCRB', 'NDUFS6', 'ATP5F1E', 'MAP2K6']",0.7480047641473914,0,0,4
71,MAPK signaling pathway,0.5714288240642368,1.0868055555555556,0.6081930668146951,"['CD14', 'MAP2K6']",0.7480047641473914,0,0,2
72,Adrenergic signaling in cardiomyocytes,0.5840850046152615,1.2426614481409002,0.6681899350690478,['CREB5'],0.7480047641473914,0,0,1
73,Cholinergic synapse,0.5840850046152615,1.2426614481409002,0.6681899350690478,['CREB5'],0.7480047641473914,0,0,1
74,Yersinia infection,0.5840850046152615,1.2426614481409002,0.6681899350690478,['MAP2K6'],0.7480047641473914,0,0,1
75,Fluid shear stress and atherosclerosis,0.5840850046152615,1.2426614481409002,0.6681899350690478,['MAP2K6'],0.7480047641473914,0,0,1
76,GABAergic synapse,0.5840850046152615,1.2426614481409002,0.6681899350690478,['SLC6A1'],0.7480047641473914,0,0,1
77,Legionellosis,0.5840850046152615,1.2426614481409002,0.6681899350690478,['CD14'],0.7480047641473914,0,0,1
78,Shigellosis,0.6019360160657118,1.0212418300653594,0.5183865654893394,"['CAPNS1', 'CD14']",0.7480047641473914,0,0,2
79,Lipid and atherosclerosis,0.6019360160657118,1.0212418300653594,0.5183865654893394,"['CD14', 'MAP2K6']",0.7480047641473914,0,0,2
80,Parkinson disease,0.6168588724429527,0.9624413145539906,0.46496984828771454,"['UQCRB', 'NDUFS6', 'ATP5F1E']",0.7480047641473914,0,0,3
81,Toxoplasmosis,0.6275562249506059,1.0856164383561644,0.5058125935638998,['MAP2K6'],0.7480047641473914,0,0,1
82,cAMP signaling pathway,0.6275562249506059,1.0856164383561644,0.5058125935638998,['CREB5'],0.7480047641473914,0,0,1
83,mTOR signaling pathway,0.6275562249506059,1.0856164383561644,0.5058125935638998,['PRR5'],0.7480047641473914,0,0,1
84,Salmonella infection,0.6308115841434567,0.9629629629629629,0.44368331689471946,"['CD14', 'MAP2K6']",0.7480047641473914,0,0,2
85,Non-alcoholic fatty liver disease,0.6580625716339038,0.9108187134502924,0.3811368801920315,"['UQCRB', 'NDUFS6']",0.7480047641473914,0,0,2
86,Alzheimer disease,0.6621076005513306,0.893152015541525,0.36827086764897315,"['UQCRB', 'NDUFS6', 'ATP5F1E']",0.7480047641473914,0,0,3
87,Spinocerebellar ataxia,0.6665388987452002,0.9634703196347032,0.3908382659065015,['TBPL1'],0.7480047641473914,0,0,1
88,Chemical carcinogenesis,0.6665388987452002,0.9634703196347032,0.3908382659065015,['CREB5'],0.7480047641473914,0,0,1
89,Dopaminergic synapse,0.6665388987452002,0.9634703196347032,0.3908382659065015,['CREB5'],0.7480047641473914,0,0,1
90,Pertussis,0.6665388987452002,0.9634703196347032,0.3908382659065015,['CD14'],0.7480047641473914,0,0,1
91,Transcriptional misregulation in cancer,0.7014907812980178,0.8657534246575342,0.3069507304576939,['CD14'],0.778577680341756,0,0,1
92,Cytokine-cytokine receptor interaction,0.73282352767807,0.7858032378580324,0.24426721905518403,['LTBR'],0.8045127858204899,0,0,1
93,Phagosome,0.7609072768916264,0.7191780821917808,0.196510932143071,['CD14'],0.8175705847452582,0,0,1
94,Retrograde endocannabinoid signaling,0.7609072768916264,0.7191780821917808,0.196510932143071,['NDUFS6'],0.8175705847452582,0,0,1
95,Cardiac muscle contraction,0.7860747852866616,0.6628029504741834,0.1595388868599391,['UQCRB'],0.8270161803536752,0,0,1
96,Rap1 signaling pathway,0.7860747852866616,0.6628029504741834,0.1595388868599391,['MAP2K6'],0.8270161803536752,0,0,1
97,Tuberculosis,0.8086251545766554,0.6144814090019569,0.13052802627368396,['CD14'],0.833378985839206,0,0,1
98,Epstein-Barr virus infection,0.8086251545766554,0.6144814090019569,0.13052802627368396,['MAP2K6'],0.833378985839206,0,0,1
99,Human immunodeficiency virus 1 infection,0.8288271921774776,0.5726027397260274,0.10750249910800473,['MAP2K6'],0.8455711758578306,0,0,1
100,Kaposi sarcoma-associated herpesvirus infection,0.8906293845835376,0.44917087238644554,0.052026066348272976,['MAP2K6'],0.8906293845835376,0,0,1
101,PI3K-Akt signaling pathway,0.8906293845835376,0.44917087238644554,0.052026066348272976,['CREB5'],0.8906293845835376,0,0,1
